Announced Tue, 11 Aug · 17:59 IST
Sandu Pharma Q1 FY27 PAT up 28 percent, board approves results and new auditor
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-5.7%1-day move
₹39.25
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-5.7-3.3-4.4-3.2-3.2-3.2-3.1-5.8——
Up moveDown movePending
AI summary
Board approved Q1 FY27 unaudited results. Revenue from operations at Rs 1638.88 lakhs versus Rs 1669.90 lakhs in Q1 FY26. Profit after tax rose to Rs 28.53 lakhs from Rs 22.33 lakhs, up about 28 percent. EPS at Rs 0.37 versus Rs 0.23. Record date September 4, 2026 for FY26 dividend. 41st AGM on September 11, 2026. Dave and Dave appointed statutory auditor for five years. Member approval sought for material related party transactions with Sandu Brothers.
Likely market impact
Stable quarter with PAT growth despite slight revenue dip. Dividend record date September 4, 2026 and AGM on September 11. New auditor needs shareholder approval.